Teva Shocks Skeptics With Stock Rebound

New CEO and successful patient outreach drove Israeli drug giant's shares to three-year high.

Yoram Gabison
Yoram Gabison
Send in e-mailSend in e-mail
Yoram Gabison
Yoram Gabison

Comments